{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T10:57:38Z","timestamp":1767178658444,"version":"build-2238731810"},"reference-count":37,"publisher":"Public Library of Science (PLoS)","issue":"11","license":[{"start":{"date-parts":[[2021,11,15]],"date-time":"2021-11-15T00:00:00Z","timestamp":1636934400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:p>Increasing oncological treatment costs are a major global concern with the risk of entailing two-tiered health care. Among cost determining factors is the price of individual drugs. In recognition of the central role of this factor, we present a comprehensive overview of the development of monthly prices of oncological drugs introduced over the last 15 years in Switzerland. We identified all oncological drugs newly reimbursed by mandatory health insurance in 2005\u20132019, and searched public repositories for their package prices, indications with approval dates, and treatment regimens for the calculation of (indication-specific) monthly prices. We found 81 products covering 77 different substances (39.5% protein kinase inhibitors, 21.0% monoclonal antibodies). Most indications related to the topography \u201cblood\u201d, followed by \u201clung and thorax\u201d and \u201cdigestive tract\u201d. From 2005\u20132009 to 2015\u20132019, the median monthly product price over all distinct indications of all products decreased by 7.56% (CHF 5,699 [interquartile range 4,483\u20137,321] to CHF 5,268 [4,19\u20136,967]), whereas it increased by 73.7% for monoclonal antibodies. In December 2019, six products had monthly prices over CHF 10,000, all approved for hematological or dermatological cancers. Our analysis suggests that individual price developments of oncological drugs are presently not the major driver of rising cancer treatment costs. However, rising launch prices of some new, mostly hematological drugs are of concern and require continued monitoring.<\/jats:p>","DOI":"10.1371\/journal.pone.0259936","type":"journal-article","created":{"date-parts":[[2021,11,15]],"date-time":"2021-11-15T13:30:14Z","timestamp":1636983014000},"page":"e0259936","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":2,"title":["Price trends of reimbursed oncological drugs in Switzerland in 2005\u20132019: A descriptive analysis"],"prefix":"10.1371","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1484-6934","authenticated-orcid":true,"given":"Yael","family":"Rachamin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christoph Jakob","family":"Ackermann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4422-7250","authenticated-orcid":true,"given":"Oliver","family":"Senn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1564-5296","authenticated-orcid":true,"given":"Thomas","family":"Grischott","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2021,11,15]]},"reference":[{"issue":"10","key":"pone.0259936.ref001","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1016\/S1470-2045(11)70141-3","article-title":"Delivering affordable cancer care in high-income countries","volume":"12","author":"R Sullivan","year":"2011","journal-title":"The Lancet Oncology"},{"key":"pone.0259936.ref002","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.ejca.2016.12.014","article-title":"Policy and priorities for national cancer control planning in low- and middle-income countries: Lessons from the Association of Southeast Asian Nations (ASEAN) Costs in Oncology prospective cohort study","volume":"74","author":"ACTION Study Group","year":"2017","journal-title":"Eur J Cancer"},{"issue":"2","key":"pone.0259936.ref003","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1093\/annonc\/mdw548","article-title":"Oncology drug costs-the imaginary crisis?","volume":"28","author":"R Turck","year":"2017","journal-title":"Annals of oncology: official journal of the European Society for Medical Oncology"},{"key":"pone.0259936.ref004","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.canep.2017.11.007","article-title":"Incidence, prevalence, mortality, disability-adjusted life years and risk factors of cancer in Australia and comparison with OECD countries, 1990\u20132015: findings from the Global Burden of Disease Study 2015","volume":"52","author":"YA Melaku","year":"2018","journal-title":"Cancer epidemiology"},{"issue":"1","key":"pone.0259936.ref005","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1186\/s13045-019-0783-9","article-title":"Incidence and death in 29 cancer groups in 2017 and trend analysis from 1990 to 2017 from the Global Burden of Disease Study","volume":"12","author":"L Lin","year":"2019","journal-title":"Journal of hematology & oncology"},{"issue":"5","key":"pone.0259936.ref006","doi-asserted-by":"crossref","first-page":"e280","DOI":"10.1200\/JOP.17.00058","article-title":"Examining Trends in Cost and Clinical Benefit of Novel Anticancer Drugs Over Time","volume":"14","author":"R Saluja","year":"2018","journal-title":"Journal of oncology practice"},{"key":"pone.0259936.ref007","volume-title":"Medicines, vaccines and health products: cancer medicines: report by the Director-General","author":"B Executive","year":"2018"},{"key":"pone.0259936.ref008","article-title":"Die Pharmaindustrie setzt das Schweizer Gesundheitssystem mit exorbitanten Preisforderungen unter Stress","author":"D Feldges","year":"2019","journal-title":"Neue Z\u00fcrcher Zeitung"},{"issue":"3","key":"pone.0259936.ref009","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.healthpol.2019.12.006","article-title":"Accessibility of cancer drugs in Switzerland: Time from approval to pricing decision between 2009 and 2018","volume":"124","author":"KN Vokinger","year":"2020","journal-title":"Health policy (Amsterdam, Netherlands)"},{"issue":"6","key":"pone.0259936.ref010","doi-asserted-by":"crossref","first-page":"e538","DOI":"10.1200\/JOP.2016.014431","article-title":"Cancer Drugs: An International Comparison of Postlicensing Price Inflation","volume":"13","author":"P Savage","year":"2017","journal-title":"Journal of oncology practice"},{"key":"pone.0259936.ref011","volume-title":"Cancer prevention and control in the context of an integrated approach","author":"A World Health","year":"2017"},{"issue":"7","key":"pone.0259936.ref012","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1001\/jamaoncol.2016.0648","article-title":"Drug Pricing Trends for Orally Administered Anticancer Medications Reimbursed by Commercial Health Plans, 2000\u20132014","volume":"2","author":"SB Dusetzina","year":"2016","journal-title":"JAMA oncology"},{"issue":"1","key":"pone.0259936.ref013","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1257\/jep.29.1.139","article-title":"Pricing in the Market for Anticancer Drugs","volume":"29","author":"DH Howard","year":"2015","journal-title":"The journal of economic perspectives: a journal of the American Economic Association"},{"key":"pone.0259936.ref014","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.ejca.2020.11.031","article-title":"The use of \u2019added benefit\u2019 to determine the price of new anti-cancer drugs in France, 2004\u20132017","volume":"145","author":"MA Rodwin","year":"2021","journal-title":"Eur J Cancer"},{"issue":"4","key":"pone.0259936.ref015","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1200\/JCO.2016.72.2124","article-title":"Trajectories of Injectable Cancer Drug Costs After Launch in the United States","volume":"36","author":"N Gordon","year":"2018","journal-title":"Journal of clinical oncology: official journal of the American Society of Clinical Oncology"},{"issue":"6","key":"pone.0259936.ref016","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1038\/bjc.2015.56","article-title":"Development and economic trends in cancer therapeutic drugs: a 5-year update 2010\u20132014","volume":"112","author":"P Savage","year":"2015","journal-title":"British journal of cancer"},{"issue":"5","key":"pone.0259936.ref017","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1377\/hlthaff.2015.1145","article-title":"Steady Increase In Prices For Oral Anticancer Drugs After Market Launch Suggests A Lack Of Competitive Pressure","volume":"35","author":"CS Bennette","year":"2016","journal-title":"Health affairs (Project Hope)"},{"key":"pone.0259936.ref018","article-title":"Analysis of Launch and Postapproval Cancer Drug Pricing, Clinical Benefit, and Policy Implications in the US and Europe","author":"KN Vokinger","year":"2021","journal-title":"JAMA oncology"},{"issue":"5","key":"pone.0259936.ref019","first-page":"458","volume":"44","author":"DJ Karikios","year":"2014","journal-title":"Rising cost of anticancer drugs in Australia"},{"key":"pone.0259936.ref020","author":"Swiss Federal Office of Public Health"},{"key":"pone.0259936.ref021","article-title":"WHO Collaborating Centre for Drug Statistics Methodology","journal-title":"Anatomical Therapeutic Chemical Classification (ATC)\/Defined Daily Dose (DDD) Index Oslo: WHO Collaborating Centre for Drug Statistics Methodology"},{"key":"pone.0259936.ref022","author":"Swiss Federal Office of Public Health","journal-title":"Index Therapeuticus Registry: Swiss Federal Office of Public Health"},{"key":"pone.0259936.ref023","volume-title":"Swiss drug compendium","author":"HCI Solutions AG"},{"key":"pone.0259936.ref024","unstructured":"Swiss Agency for Therapeutic Products. Swissmedic Journal: Swiss Agency for Therapeutic Products; 2020 [Available from: https:\/\/www.swissmedic.ch\/swissmedic\/en\/home\/about-us\/publications\/swissmedic-journal.html."},{"key":"pone.0259936.ref025","author":"World Health Organization","year":"2019","journal-title":"International Statistical Classification of Diseases and Related Health Problems, 10th Revision, Chapter II: Neoplasms: World Health Organization"},{"key":"pone.0259936.ref026","unstructured":"Swiss Federal Statistical Office. Consumer Price Index\u2014Inflation Calculator: Federal Statistical Office; [Available from: https:\/\/lik-app.bfs.admin.ch\/en\/lik\/rechner."},{"key":"pone.0259936.ref027","volume-title":"R: A Language and Environment for Statistical Computing","author":"R Core Team","year":"2019"},{"key":"pone.0259936.ref028","author":"BD Ripley","journal-title":"loess: Local Polynomial Regression Fitting"},{"key":"pone.0259936.ref029","journal-title":"Swiss Federal Office of Public HealthTriennial review of drugs Federal Office of Public Health"},{"issue":"5","key":"pone.0259936.ref030","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1016\/S1470-2045(20)30139-X","article-title":"Prices and clinical benefit of cancer drugs in the USA and Europe: a cost-benefit analysis","volume":"21","author":"KN Vokinger","year":"2020","journal-title":"The Lancet Oncology."},{"key":"pone.0259936.ref031","unstructured":"\u201eExzessiv \u00fcberh\u00f6hte Preise\u201c\u2013Aspen verspricht f\u00fcr sechs Altzytostatika Preissenkungen um 73%. arznei-telegramm. 2020\/08\/28:63."},{"key":"pone.0259936.ref032","author":"Swiss National Bank (SNB).","journal-title":"Interest rates, yields and foreign exchange market"},{"issue":"9","key":"pone.0259936.ref033","doi-asserted-by":"crossref","first-page":"A467","DOI":"10.1016\/j.jval.2017.08.391","article-title":"Systematic Literature Review On Multi-Indication Pricing Models In Oncological Drugs","volume":"20","author":"A Manganelli","year":"2017","journal-title":"Value in Health"},{"issue":"87","key":"pone.0259936.ref034","article-title":"Pharmaceutical Expenditure And Policies: Past Trends And Future Challenges","author":"A Belloni","year":"2016","journal-title":"OECD Health Working Papers"},{"key":"pone.0259936.ref035","article-title":"Helsana-Arzneimittelreport f\u00fcr die Schweiz 2019 [Helsana Medicines Report for Switzerland 2019]","author":"R Schneider","year":"2019","journal-title":"Helsana"},{"key":"pone.0259936.ref036","article-title":"Die Kosten der nicht\u00fcbertragbaren Krankheiten in der Schweiz: Schlussbericht","author":"S Wieser","year":"2014","journal-title":"Winterthur: Z\u00fcrcher Hochschule f\u00fcr Angewandte Wissenschaften (zhaw)"},{"issue":"1","key":"pone.0259936.ref037","doi-asserted-by":"crossref","first-page":"e0146551","DOI":"10.1371\/journal.pone.0146551","article-title":"Comparative Cost-Effectiveness of Drugs in Early versus Late Stages of Cancer; Review of the Literature and a Case Study in Breast Cancer","volume":"11","author":"E Dvortsin","year":"2016","journal-title":"PloS one"}],"updated-by":[{"DOI":"10.1371\/journal.pone.0264610","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2022,2,23]],"date-time":"2022-02-23T00:00:00Z","timestamp":1645574400000}}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0259936","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,15]],"date-time":"2021-11-15T13:30:52Z","timestamp":1636983052000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0259936"}},"subtitle":[],"editor":[{"given":"Wen-Wei","family":"Sung","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2021,11,15]]},"references-count":37,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2021,11,15]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0259936","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,15]]}}}